Table 5 Strength Outcomes. Studies Comparing Deflazacort and Prednisone.
From: Deflazacort for the treatment of Duchenne Dystrophy: A systematic review
Study (Duration of Follow up) | A. Bonifati, 2000 (12 months) | F. Angelini, 1998 (12 months) | N. Brooke, 1996 (3 months) |
|---|---|---|---|
Strength Measures | |||
MRC score * (mean change in score from baseline) | DFZ: + 1 Pred: + 0.5 No variance or P values reported. | - | - |
Average Muscle score * (mean change in score from baseline) | - | - | DFZ (low): +0.18 (+/- 0.4) DFZ (high): +0.26 (+/- 0.5) Pred: +0.27 (+/- 0.5) Standard errors imputed from p values. |
Functional Measures | |||
Timed gait | Measured but not reported. | - | - |
Timed stairs | - | - | - |
Timed chair | - | - | - |
Timed Gower | - | - | - |
Graded gait ** | DFZ: - 0.5 Pred: -0.5 Combined score from all four tests. No variance or p values reported. | - | - |
Graded stairs ** | - | - | - |
Graded chair ** | - | - | - |
Graded Gower ** | - | - | - |
Other Measures | |||
Patient reported benefit | - | Patients reported benefit on both prednisone and DFZ. No numeric representation of reported benefit was reported. | - |